These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 35999128)
1. Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66). Foo FS; Lee M; Poppe KK; Clare GC; Stiles MK; Gavin A; Webber M; Jackson R; Kerr AJ Heart Lung Circ; 2022 Nov; 31(11):1531-1538. PubMed ID: 35999128 [TBL] [Abstract][Full Text] [Related]
2. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention? Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058 [TBL] [Abstract][Full Text] [Related]
3. Heart failure clinics improve use of evidence-based heart failure therapies in patients with reduced ejection fraction following acute coronary syndrome (ANZACS-QI 48). Chan D; Doughty RN; Mazengarb J; McLachlan A; Kerr AJ N Z Med J; 2020 Jun; 133(1516):58-71. PubMed ID: 32525862 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis. Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582 [TBL] [Abstract][Full Text] [Related]
5. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry. Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210 [TBL] [Abstract][Full Text] [Related]
6. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS Eur J Heart Fail; 2021 Sep; 23(9):1499-1511. PubMed ID: 34132001 [TBL] [Abstract][Full Text] [Related]
7. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy. Malgie J; Clephas PRD; Brunner-La Rocca HP; de Boer RA; Brugts JJ Heart Fail Rev; 2023 Sep; 28(5):1221-1234. PubMed ID: 37311917 [TBL] [Abstract][Full Text] [Related]
8. Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients With Reduced Left Ventricular Ejection Fraction After Acute Coronary Syndrome (ANZACS-QI 34). Chan D; Doughty RN; Lund M; Lee M; Kerr AJ Heart Lung Circ; 2020 Sep; 29(9):1386-1396. PubMed ID: 32423781 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction. Sandhu AT; Kohsaka S; Turakhia MP; Lewis EF; Heidenreich PA JAMA Cardiol; 2022 Feb; 7(2):130-139. PubMed ID: 34757380 [TBL] [Abstract][Full Text] [Related]
10. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570 [TBL] [Abstract][Full Text] [Related]
11. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice. Smith KV; Dunning JR; Fischer CM; MacLean TE; Bosque-Hamilton JW; Fera LE; Grant JY; Zelle DJ; Matta L; Gaziano TA; MacRae CA; Scirica BM; Desai AS J Pharm Pract; 2022 Oct; 35(5):747-751. PubMed ID: 33813934 [TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971 [TBL] [Abstract][Full Text] [Related]
14. Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. Samsky MD; Lin L; Greene SJ; Lippmann SJ; Peterson PN; Heidenreich PA; Laskey WK; Yancy CW; Greiner MA; Hardy NC; Kavati A; Park S; Mentz RJ; Fonarow GC; O'Brien EC JAMA Cardiol; 2020 Mar; 5(3):292-299. PubMed ID: 31734700 [TBL] [Abstract][Full Text] [Related]
16. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of guideline-directed medical therapy among patients receiving cardiac resynchronization therapy defibrillator implantation in the National Cardiovascular Data Registry during the years 2006 to 2008. Schneider PM; Pellegrini CN; Wang Y; Fein AS; Reynolds MR; Curtis JP; Masoudi FA; Varosy PD Am J Cardiol; 2014 Jun; 113(12):2052-6. PubMed ID: 24793671 [TBL] [Abstract][Full Text] [Related]
18. Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure. Packer M JACC Heart Fail; 2019 Oct; 7(10):902-906. PubMed ID: 31521684 [No Abstract] [Full Text] [Related]
19. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. Greene SJ; Ezekowitz JA; Anstrom KJ; Demyanenko V; Givertz MM; Piña IL; O'Connor CM; Koglin J; Roessig L; Hernandez AF; Armstrong PW; Mentz RJ J Card Fail; 2022 Jul; 28(7):1063-1077. PubMed ID: 35301107 [TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. de Diego C; González-Torres L; Núñez JM; Centurión Inda R; Martin-Langerwerf DA; Sangio AD; Chochowski P; Casasnovas P; Blazquéz JC; Almendral J Heart Rhythm; 2018 Mar; 15(3):395-402. PubMed ID: 29146274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]